Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03067857 |
Recruitment Status : Unknown
Verified June 2018 by Stem Cells Arabia.
Recruitment status was: Active, not recruiting
First Posted : March 1, 2017
Last Update Posted : June 6, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Motor Neuron Disease Amyotrophic Lateral Sclerosis Primary Lateral Sclerosis Progressive Muscular Atrophy Progressive Bulbar Palsies | Biological: Stem Cells | Phase 1 Phase 2 |
A motor neuron disease (MND) is any of several neurological disorders that selectively affect motor neurons, the cells that control voluntary muscles of the body. They include amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), progressive bulbar palsy (PBP) and pseudobulbar palsy; spinal muscular atrophies are also sometimes included in the group.They are neurodegenerative diseases that cause increasing disability and eventually, death.
In spite of intensive research, motor neuron diseases (MNDs) are still incurable. Some of the key factors in this failure to find a cure have been the lack of human cell-based disease models for molecular analysis and drug screening and the difficulty of obtaining homogeneous populations of specific cell types for clinical applications. Stem cell biology has the potential to transform our understanding of disease processes and to revolutionize our approach to develop novel therapies for MNDs.
In this study, the investigators suggest a protocol for the treatment of MND by transplantation of purified autologous bone marrow-derived stem cells via the intrathecal and intravenous route.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Autologous Purified Bone-Marrow-Derived Stem Cell Therapy for Motor Neuron Disease |
Study Start Date : | September 2016 |
Estimated Primary Completion Date : | January 2019 |
Estimated Study Completion Date : | August 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Stem Cells
Intravenous and Intrathecal thecal transplantation via interventional radiology of purified autologous bone-marrow derived specific stem cell populations.
|
Biological: Stem Cells
Autologous bone marrow-derived stem cell populations injected via the intravenous and intrathecal routes. |
- Changes in Functional Rating Scale - via questionnaire [ Time Frame: 6 months ]
- Change in Appel Scale [ Time Frame: 4 months ]
- Change in SF-36 (The Short Form (36) Health Survey is a 36 Item) [ Time Frame: 4 months ]
- Change in Forced Vital Capacity (FVC) [ Time Frame: 4 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 24 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients age 24-20 years old
- Patients with the diagnosis of definite Motor Neuron Disease
Exclusion Criteria:
- HIV/HBV/HCV
- Malignancies
- Bleeding
- Pneumonia
- Renal failure
- liver dysfunction
- Severe anemia (hb < 8)
- Bone Marrow diseases
- Pregnancy and lactation
- Acute medical conditions/infections such as respiratory infections
- ventilatory support
Responsible Party: | Stem Cells Arabia |
ClinicalTrials.gov Identifier: | NCT03067857 |
Other Study ID Numbers: |
SCA-MND1 |
First Posted: | March 1, 2017 Key Record Dates |
Last Update Posted: | June 6, 2018 |
Last Verified: | June 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Motor Neuron Disease Amyotrophic Lateral Sclerosis Muscular Atrophy Muscular Atrophy, Spinal Bulbar Palsy, Progressive Sclerosis Pathologic Processes Atrophy Pathological Conditions, Anatomical Neurodegenerative Diseases |
Nervous System Diseases Neuromuscular Diseases Spinal Cord Diseases Central Nervous System Diseases TDP-43 Proteinopathies Proteostasis Deficiencies Metabolic Diseases Neuromuscular Manifestations Neurologic Manifestations |